1011 On Other Exchanges
1011 is not on other exchanges.

china nt pharma group co ltd (1011) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHINA NT PHARMA GROUP CO LTD (1011)

Related News

No related news articles were found.

china nt pharma group co ltd (1011) Related Businessweek News

No Related Businessweek News Found

china nt pharma group co ltd (1011) Details

China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical and vaccine products in the People’s Republic of China. It operates through three segments: Third-Party Pharmaceutical Promotion and Sales; Proprietary Products Production and Sales; and Third-Party Vaccines and Other Pharmaceuticals. The Third-Party Pharmaceutical Promotion and Sales segment engages in selling and marketing third-party manufactured pharmaceutical products to customers, as well as providing marketing and promotion services. The Proprietary Products Production and Sales segment is involved in the production and sale of NT branded products and generic drugs. The Third-Party Vaccines and Other Pharmaceuticals segment provides supply chain services for pharmaceutical/vaccine products. The company is also involved in the trading of prescription medicines; and provision of logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Shanghai, the People's Republic of China.

582 Employees
Last Reported Date: 03/21/17
Founded in 1995

china nt pharma group co ltd (1011) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: CNY6.5M
Executive Director
Total Annual Compensation: --
Vice President, Executive Director and Chairm...
Total Annual Compensation: CNY942.0K
Compensation as of Fiscal Year 2015.
china nt pharma group co ltd
China NT Pharma Group Company Limited Recommends Final Dividend for the Year Ended December 31, 2016, Payable on July 3, 2017

The board of China NT Pharma Group Company Limited recommended final dividend of HK 2.5 cents per share for the year ended December 31, 2016, representing an increase of 150% as compared with the final dividend of HK 1.0 cent per share for the corresponding period last year. The final dividend will be payable on July 3, 2017.

China NT Pharma Group Company Limited Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016

China NT Pharma Group Company Limited reported audited consolidated earnings results for the full year ended December 31, 2016. For the year, the company reported revenue of RMB 915,119,000 compared to RMB 847,726,000 for the same period a year ago. Profit from operations was RMB 185,666,000 compared to RMB 135,957,000 last year. Profit before taxation was RMB 156,603,000 compared to RMB 100,705,000 last year. Profit attributable to equity holders of the company was RMB 116,181,000 or 7.42 cents per diluted share compared to RMB 87,694,000 or 6.14 cents per diluted share last year. Total capital expenditure increased by RMB 926.5 million or 797.3% to RMB 1,042.7 million for the year ended 31 December 2016, as compared to RMB 116.2 million for the year ended 31 December 2015. The capital expenditure was mainly used for acquiring the exclusive intellectual property rights and distribution rights relating to Miacalcic Injectable drug products.

China NT Pharma Group Company Limited to Report Fiscal Year 2016 Results on Mar 21, 2017

China NT Pharma Group Company Limited announced that they will report fiscal year 2016 results on Mar 21, 2017


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1011 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1011.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1011 Industry Range
Price/Earnings 19.2x
Price/Sales 2.4x
Price/Book 2.2x
Price/Cash Flow 19.1x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA NT PHARMA GROUP CO LTD, please visit www.ntpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.